Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2B

American Journal of Gastroenterology

Volumn 93, Issue 1, 1998, Pages 39-43

  Sim, Howe ^a   Yim, Colina ^a   Krajden, Mel ^a   Heathcote, Jenny ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; VIREMIA;

ADULT; AGED; ALANINE TRANSAMINASE; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS;

EID: 0032422483     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.039_c.x     Document Type: Article

References (30)

1. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alfa interferon: A preliminary report. N Engl J Med. 315:1986;1575-1578.
2. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med. 321:1989;1506-1510.
3. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial. N Engl J Med. 321:1989;1501-1506.
4. Tine F, Magrin S, Craxi A, et al. Interferon for non-A, non-B chronic hepatitis: A meta-analysis of randomized clinical trials. J Hepatol. 13:1991;192-199.
5. Chemello L, Cavalletto L, Casarin C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. Ann Intern Med. 124:1996;1058-1060.
6. Vento S, Cainelli F, Concia E. Lack of sustained efficacy of interferon alpha in patients with chronic hepatitis C. Hepatology. 24:1996;163A. (abstract).
7. Reichard O, Glaumann H, Fryden A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology. 21:1995;918-922.
8. Simmonds P. Variability of hepatitis C virus. Hepatology. 21:1995;570-583.
9. Takada N, Takase S, Takada A, et al. Differences in the hepatitis C virus genotypes in different countries. J Hepatol. 17:1993;277-283.
10. Nousbaum J, Stanislas P, Nalpas B, et al. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med. 122:1995;161-168.
11. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: Relationship to genotypes of hepatitis C virus. Hepatology. 16:1992;293-299.
12. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 332:1995;1457-1462.
13. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 341:1993;1501-1504.
14. Lau JYN, Mizokami M, Kolberg JA, et al. Application of six hepatitis C virus subtyping systems to sera of patients with chronic hepatitis C in the United States. J Infect Dis. 171:1994;281-289.
15. Simmonds P, Alberti A, Bonino F, et al. A proposed system for nomenclature of genotypes of hepatitis C virus. Hepatology. 19:1994;1321-1324.
16. Davidson F, Simmonds P, Ferguson JC, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol. 76:1995;1197-1204. (Pt 5).
17. Lau JYN, Simmonds P, Urdea MS. Implications of variations of "conserved" regions of hepatitis C virus genome. Lancet. 346:1995;425-426.
18. Esteban JI, Lopez-Talavera JC, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med. 115:1991;443-449.
19. Naito M, Hayashi N, Hagiwara H, et al. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology. 19:1994;811-815.
20. Boyer N, Marcellin P, Duchatelle V, et al. Sustained response after alpha interferon therapy in patients with chronic hepatitis C. Hepatology. 22:1995;291A. (abstract).
21. Chemello L, Pontiso P, Rose KA, et al. The long-term response to interferon-alfa in chronic hepatitis C is influenced by dose and duration of treatment and the HCV serotype. J Hepatol. 18:1993;S10. (abstract).
22. Shiffman ML, Hofmann CM, Luketic VAC, et al. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology. 24:1995;21-25.
23. Reichen J, Solioz M, Buhler H, et al. Low-dose interferon in chronic non-A, non-B hepatitis: Effects on quantitative liver function and structure in a randomized, controlled, multicentre trial. Clin Investigator. 71:1993;888-893.
24. Sanchez-Tapias JM, Forns X, Ampurdanes S, et al. Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial. Gut. 38:1996;603-609.
25. Hagiwara H, Hayashi N, Mita E, et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology. 17:1993;545-550.
26. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology. 21:1995;291-297.
27. Yuki N, Hayashi N, Kasahara A, et al. Pretreatment viral load and response to prolonged interferon-alpha course for chronic hepatitis C. J Hepatol. 22:1995;457-463.
28. Weiner AJ, Geysen HM, Christopherson C, et al. Evidence for immune selection of hepatitis C virus putative envelope glycoprotein variants: Potential role in chronic HCV infections. Proc Natl Acad Sci USA. 89:1992;3468-3472.
29. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 334:1996;77-81.
30. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology. 19:1994;1088-1094.